The Future of the Aging Eye
AnnMarie Hipsley, the Founder and CEO of Ace Vision Group (AVG), a Delaware, USA- based company developing innovative therapeutics for age-related ocular dysfunctions, talks to The Ophthalmologist about her background and work with AVG, and the company’s short- and long-term goals.
She explains how the Group has utilized artificial intelligence and virtual reality platforms to develop the Next Gen VisioLite laser, paints a broad picture of the current gaps in available treatment models for age-related eye diseases, such as presbyopia, and goes into detail about how Laser Scleral Microporation Therapeutic Laser Rejuvenation (LSM) eye therapy sits within the future landscape of treatments for these disorders.
Explore More Articles
Laser scleral microporation has high satisfaction in emmetropic presbyopes
SAN DIEGO — In this Healio Video Perspective from the ASCRS meeting, Robert Ang, MD, discusses 18-month study outcomes of laser scleral microporation in emmetropic presbyopes. “Our studies show that the patients have high patient satisfaction with laser scleral microporation treatment,” he said. “It is safe and effective, and it has great potential for this segment of …
read morePathogenesis of Presbyopia: A New Understanding of an Age-Old Disease
FOR MOST OF HISTORY, PRESBYOPIA has been defined as a “normal” refractive error caused by age, with discussion limited to the loss of near vision beginning in our 40s. Because we have had no effective therapeutic interventions available, presbyopia has been accepted as a natural part of life and treated primarily by changing power at either …
read moreAce Vision Group to Present Nine New Sets of Scientific Data Focused on Laser Scleral Microporation at the ESCRS Annual Meeting
Ace Vision Group (AVG) announced it will present nine sets of research on the effectiveness of Laser Scleral Microporation (LSM) at the annual congress of the European Society of Cataract and Refractive Surgeons (ESCRS). LSM is an ultra-minimally invasive procedure with a novel therapeutic approach to treating the aging eye.
read more